HI SM. Was about to have a look at the references you referred me to in the ARX prospectus regarding synthetics when I saw Hottod had already done my job for me. Great job Hottod. Interesting ARX based their claims on very old studies (2007-2014) when they could have easily referenced the many more recent studies utilising BTM. Maybe they haven't heard of BTM? Or perhaps they deliberately chose not to reference those results? What do you think SM? Because that's another alarm bell to me.
Should PNV consider taking over ARX?, page-52
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.99 |
Change
0.010(0.51%) |
Mkt cap ! $1.371B | |||
| Open | High | Low | Value | Volume |
| $1.98 | $1.99 | $1.94 | $2.913M | 1.478M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 10216 | $1.96 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.99 | 3689 | 1 |
View Market Depth
| Last trade - 16.10pm 06/11/2024 (20 minute delay) ? |
| PNV (ASX) Chart |